Abstract:The use of radioisotopes in nuclear medicine is essential for diagnosing and treating cancer. The optimization of their production is a key factor in maximizing the production yield and minimizing the associated costs. An efficient approach to this problem is the use of Monte Carlo simulations prior to experimentation. By predicting isotopes yields, one can study the isotope of interest expected activity for different energy ranges. One can also study the target contamination with other radioisotopes, especially undesired radioisotopes of the wanted chemical element which are difficult to separate from the irradiated target and might result in increasing the dose when delivering the radiopharmaceutical product to the patient. The aim of this work is to build and validate a Monte Carlo simulation platform using the GEANT4 toolkit to model the solid target system of the South Australian Health and Medical Research Institute (SAHMRI) GE Healthcare PETtrace cyclotron. It includes a GEANT4 Graphical User Interface (GUI) where the user can modify simulation parameters such as the energy, shape and current of the proton beam, the target geometry and material, the foil geometry and material and the time of irradiation. The paper describes the simulation and presents a comparison of simulated and experimental/theoretical yields for various nuclear reactions on an enriched nickel 64 target using the GEANT4 physics model QGSP_BIC_AllHP, a model recently developed to evaluate with high precision the interaction of protons with energies below 200MeV available in Geant4 version 10.1. The simulation yield of the (64)Ni(p,n)(64)Cu reaction was found to be 7.67±0.074 mCi·μA(-1) for a target energy range of 9-12MeV. Szelecsenyi et al. (1993) gives a theoretical yield of 6.71mCi·μA(-1) and an experimental yield of 6.38mCi·μA(-1). The (64)Ni(p,n)(64)Cu cross section obtained with the simulation was also verified against the yield predicted from the nuclear database TENDL and compared to experimental yield obtained from literature.

Investigation of 209Bi (α,2n)211At reaction route for the production of α-emitter 211At

Study on Production Method of the {sup 178m2}hf Isomer for Induced Gamma Emission

An attempt to explore the production routes of Astatine radionuclides: Theoretical approach

Investigation of Production Possibility of Medical Isotope 155Tb on Cyclotron C18/18

Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy

Investigation of production of medical 82Sr and 68Ge for 82Sr/82Rb and 68Ge/68Ga generators via proton accelerator

Production of Polonium-208, 209 and 210 for use in nuclear battery via particle accelerator

The effects of nuclear level density model and alpha optical model potential to the excitation functions of novel therapeutic radionuclides

Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide

GEANT4 simulation of cyclotron radioisotope production in a solid target

Production possibility of 161Tb utilizing secondary neutrons generated by protons from a low-energy cyclotron onto an isotope production target

Evaluation of the cross section data for the low and medium energy cyclotron production of 77Br radionuclide

Investigation of a tellurium-packed column for isolation of astatine-211 from irradiated bismuth targets and demonstration of a semi-automated system

Optimized simulations of 50Ti(p,α) and 49Ti(d,α) reactions for hospital-cyclotron production of 47Sc

Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with $γ$ Beams of High Intensity and Large Brilliance

An analytical approach to optimization of isotope production by bremsstrahlung radiation

Investigation of the cross sections of natCu(α,x)66,67Ga, 65Zn reactions

Nuclear model calculation and targetry recipe for production of 110mIn

Comparative study of 155Tb production via 155Dy precursor with p, d and α beams on natural targets for medical applications

A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial

A new method in the production of Ac-227, Ra-228, Th-228 and U-232 on Thorium target from different perspective for use in Radioisotope Power Systems and Nuclear Batteries